192 related articles for article (PubMed ID: 17157627)
21. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer.
Hauth EA; Antoch G; Stattaus J; Kuehl H; Veit P; Bockisch A; Kimmig R; Forsting M
Eur J Radiol; 2005 Nov; 56(2):263-8. PubMed ID: 16233894
[TBL] [Abstract][Full Text] [Related]
22. The impact of PET/CT in the management of recurrent ovarian cancer.
Simcock B; Neesham D; Quinn M; Drummond E; Milner A; Hicks RJ
Gynecol Oncol; 2006 Oct; 103(1):271-6. PubMed ID: 16626793
[TBL] [Abstract][Full Text] [Related]
23. The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging.
Manegold-Brauer G; Bellin AK; Tercanli S; Lapaire O; Heinzelmann-Schwarz V
Arch Gynecol Obstet; 2014 Mar; 289(3):491-8. PubMed ID: 24253338
[TBL] [Abstract][Full Text] [Related]
24. Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer.
Barranger E; Kerrou K; Petegnief Y; David-Montefiore E; Cortez A; Daraï E
Gynecol Oncol; 2005 Jan; 96(1):241-4. PubMed ID: 15589609
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis--report of the Radiology Diagnostic Oncology Group.
Kurtz AB; Tsimikas JV; Tempany CM; Hamper UM; Arger PH; Bree RL; Wechsler RJ; Francis IR; Kuhlman JE; Siegelman ES; Mitchell DG; Silverman SG; Brown DL; Sheth S; Coleman BG; Ellis JH; Kurman RJ; Caudry DJ; McNeil BJ
Radiology; 1999 Jul; 212(1):19-27. PubMed ID: 10405715
[TBL] [Abstract][Full Text] [Related]
26. [ULTRASOUND CRITERIA OR THE OPERABILITY AND EFFICACY OF THE TREATMENT OF THE MALIGNANT EPITHELIAL OVARIAN TUMOURS].
Shkarbun KD; Shkarbun LI
Lik Sprava; 2015; (7-8):105-9. PubMed ID: 27491160
[TBL] [Abstract][Full Text] [Related]
27. Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT: Part 2.
Alt CD; Brocker KA; Eichbaum M; Sohn C; Arnegger FU; Kauczor HU; Hallscheidt P
Strahlenther Onkol; 2011 Nov; 187(11):705-14. PubMed ID: 22037656
[TBL] [Abstract][Full Text] [Related]
28. [A retrospective study of ovarian cancer with a median follow of 42 months].
Raherinantenaina F; Rakotomena SD; Hasiniatsy NR; Rakototiana FA; Rafaramino F; Ratsimba HN
Pan Afr Med J; 2015; 20():211. PubMed ID: 26113942
[TBL] [Abstract][Full Text] [Related]
29. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
30. Radiological staging of ovarian carcinoma.
Moyle P; Addley HC; Sala E
Semin Ultrasound CT MR; 2010 Oct; 31(5):388-98. PubMed ID: 20974358
[TBL] [Abstract][Full Text] [Related]
31. Staging of advanced ovarian cancer: comparison of imaging modalities--report from the Radiological Diagnostic Oncology Group.
Tempany CM; Zou KH; Silverman SG; Brown DL; Kurtz AB; McNeil BJ
Radiology; 2000 Jun; 215(3):761-7. PubMed ID: 10831697
[TBL] [Abstract][Full Text] [Related]
32. Current update on borderline ovarian neoplasms.
Lalwani N; Shanbhogue AK; Vikram R; Nagar A; Jagirdar J; Prasad SR
AJR Am J Roentgenol; 2010 Feb; 194(2):330-6. PubMed ID: 20093592
[TBL] [Abstract][Full Text] [Related]
33. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.
Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S
Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908
[TBL] [Abstract][Full Text] [Related]
34. [Role of positron emission tomography in detecting recurrent epithelial ovarian carcinoma].
Zhu X; Shen K; Lang J; Wu M; Huang H; Pan L
Zhonghua Fu Chan Ke Za Zhi; 2002 Jun; 37(6):356-8. PubMed ID: 12126572
[TBL] [Abstract][Full Text] [Related]
35. Imaging of cervical lymph nodes in head and neck cancer: the basics.
Gor DM; Langer JE; Loevner LA
Radiol Clin North Am; 2006 Jan; 44(1):101-10, viii. PubMed ID: 16297684
[TBL] [Abstract][Full Text] [Related]
36. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic factors in advanced ovarian cancer patients].
Terasawa K; Sagae S
Nihon Rinsho; 2004 Oct; 62 Suppl 10():592-6. PubMed ID: 15535314
[No Abstract] [Full Text] [Related]
38. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial report.
Yuan CC; Liu RS; Wang PH; Ng HT; Yeh SH
J Reprod Med; 1999 Sep; 44(9):775-8. PubMed ID: 10509300
[TBL] [Abstract][Full Text] [Related]
39. [Ultrasonography and magnetic resonance imaging in diagnosing recurrent and metastatic ovarian cancer].
Bulanova IM; Bulanova TV; Burenchev DV
Vestn Rentgenol Radiol; 2006; (1):53-8. PubMed ID: 17195634
[TBL] [Abstract][Full Text] [Related]
40. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE
Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
